65 results on '"Scaldaferri, F"'
Search Results
2. OC.07.8: THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY.
3. OC.03.5: MULTIMODAL DYNAMIC ULTRASOUND APPROACH AS PREDICTOR OF RESPONSE IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB.
4. T.11.2: SARCOPENIA AND IBD: MOLECULAR PATHWAYS AND POTENTIAL PHARMACOLOGICAL AND MICROBIAL MODULATORS IN INVITRO MODELS OF INFLAMMATORY BOWEL DISEASE.
5. T.08.9: SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION.
6. T.05.4: RENAL LITHOGENIC RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES CORRELATES WITH MICROBIOTA COMPOSITION, URINARY PROFILE AND DIETARY INTAKE.
7. OC.18.4: MONITORING THE PSYCHOPATHOLOGICAL PROFILE OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS TREATED WITH BIOLOGICAL AGENTS.
8. OC.07.9: ENDOSCOPIC BALLOON DILATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN'S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE.
9. OC.03.2: HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS ANEMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE.
10. OC.10.6 THE ROLE OF OCTN1 IN PREDICTING INDIVIDUAL RESPONSE TO THERAPY IN ULCERATIVE COLITIS: TOWARDS A PERSONALIZED APPROACH.
11. OC.02.5 THE SOLUTE CARRIER LC22A4/OCTN1 AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE.
12. OC.09.1 THE MODERATING EFFECT OF RESILIENCE ON DEPRESSION IN PATIENTS WITH CROHN'S DISEASE.
13. OC.17.4 COMBINATION OF ADVANCED THERAPIES IN PATIENTS WITH COMPLEX INFLAMMATORY BOWEL DISEASE.
14. OC.12.6 RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN'S DISEASE.
15. OC.08.6 IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMTDERIVED MUCOSAL HEALING.
16. OC.16.6 EMERGING ROLE OF IL-33/ST2 LEVELS IN PREDICTING MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS.
17. OC.06.2 LIRAGLUTIDE TREATMENT IN OBESE DIABETIC PATIENTS MODULATES GAS PRODUCTION DURING LACTULOSE BREATH TEST: A NEW POTENTIAL TREATMENT TO MODULATE GUT MICROBIOTA.
18. OC.12.1 THE IMPACT OF TROPHIC EFFECTS OF MULTI STRAIN PROBIOTIC PREPARATION ON PARACELLULAR PERMEABILITY.
19. P.10.17 PREVALENCE OF MALNUTRITION IN IBD PATIENTS.
20. P.07.10 OCULAR MANIFESTATIONS IN A TERTIARY IBD CENTER: BETTER TO KEEP AN EYE ON.
21. OC.16.1 ALTERATIONS IN CYTOKINE EXPRESSION PROFILE IN COLON MUCOSA OF IBD PATIENTS AND IN RESPONSE TO ANTI-TNF-A TREATMENT.
22. P.07.20 FATIGUE AS A POSSIBLE MARKER OF SARCOPENIA IN INFLAMMATORY BOWEL DISEASE PATIENTS.
23. OC.02.1 IL-33 PROMOTES GUT MUCOSAL WOUND HEALING BY INDUCING MIRNA-320 TO STIMULATE EPITHELIAL RESTITUTION AND REPAIR.
24. OC.10.2 ANTI-TNF-ALPHA THERAPY INDUCES MICROBIAL AND IMMUNOLOGICAL CHANGES IN DEXTRAN SODIUM SULPHATE CHRONIC COLITIS.
25. Intestinal permeability is increased in children with irritable bowel syndrome: A case–control study.
26. OC.14.2: Critical Role of the IL-33/ST2 Axis in Colitis-Associated Colorectal Cancer.
27. P.05.9: Colitis is Associated with Muscle Function Alteration: Emerging Mechanisms of Asthenia in IBD?
28. OC.14.6: Escherichia Coli Nissle 1917 Modulate GUT Microbiota Composition in Ulcerative Colitis Patients.
29. P.05.8: Clausii in Colitis: Role and Mechanisms of Action of Bacillus Clausii in Experimental Colitis.
30. P.03.12: Breath Methane Production in Lactulose Breath Test is Affected by Gender, a Post HOC Italian Study.
31. P.07.8 IL-33/ST2 AXIS MODULATES EPITHELIAL REPAIR AND GUT MUCOSAL WOUND HEALING IN DSS-COLITIC MICE.
32. P.07.1 GUT MICROBIOTA MOLECULAR SPECTRUM IN HEALTHY CONTROLS, DIVERTICULAR DISEASE, IBS AND IBD PATIENTS: TIME FOR MICROBIAL MARKER OF GASTROINTESTINAL DISORDERS?
33. P.09.15 INCREASED ABUNDANCE OF BENEFICIAL BACTERIA IS ASSOCIATED WITH CLINICAL IMPROVEMENT AFTER RIFAXIMIN TREATMENT.
34. P.12.10 SMALL INTESTINAL BACTERIAL OVERGROWTH IS LINKED TO VASCULAR DISEASE VIA VITAMIN K2-DEPENDENT MECHANISMS.
35. First steps towards understanding the dynamic evolution of gut microbiota in different stages of liver disease.
36. P.01.1 EFFECT OF BACILLUS CLAUSII IN THE N-METHYLNITROSUREA INDUCED MODEL OF COLONRECTAL CANCER.
37. P.01.5 IL-33 TREATMENT ACCELERATES EPITHELIAL REPAIR AND GUT MUCOSAL WOUND HEALING IN DSS-COLITIC MICE.
38. OC.11.3 MUCOSAL HEALING DOES NOT CORRESPOND TO HISTOLOGICAL HEALING IN ULCERATIVE COLITIS.
39. P.06.3 PREVALENCE AND ROLE OF ALEXITHYMIA IN IBD PATIENTS.
40. P.18.4 EFFICACY OF ANTIOXIDANT THERAPY IN IMPROVING PAINFUL CHRONIC PANCREATITIS: A SYSTEMATIC REVIEW.
41. OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION.
42. OC.12.1 MORPHOLOGICAL FEATURES OF ENDOTHELIAL CELLS OF ENDOMETRIUM BEFORE AND AFTER INCUBATION WITH ANTI-TRANSGLUTAMINASE ANTIBODIES IN BOTH HEALTHY AND CELIAC WOMEN.
43. OC.13.4 MULTIPARAMETRIC EVALUATION OF CROHN'S DISEASE: INTESTINAL HEALING BEYOND MUCOSAL HEALING.
44. V.02.4 EUS-GUIDED FINE NEEDLE TISSUE ACQUISITION OF A SUBEPITHELIAL LESION IN THE DISTAL ILEUM USING THE FORWARD VIEWING ECHOENDOSCOPE.
45. P.06.9 INFLIXIMAB IS NOT INCREASING COLONIC CANCER RISK ASSOCIATED TO CHRONIC COLITIS IN MICE.
46. P.18.2 ENDOMETRIUM ENDOTHELIAL CELLS OF FERTILE WOMEN BEFORE AND AFTER ANTI-TTGA INCUBATION.
47. P.16.11 CT ENTEROGRAPHY CORRELATION WITH CLINICAL RESPONSE TO THERAPY IN PATIENTS AFFECTED BY CROHN'S DISEASE.
48. P.16.1 INFLIXIMAB AND TNF ALFA MEASUREMENT IN INTESTINAL MUCOSA OF IBD PATIENTS: A NEW TOOL FOR THE CLINIC?
49. P.06.5 DIRECT EFFECTS OF INFLIXIMAB (IFX) ON INTESTINAL MUCOSA: EXPLORING MECHANISMS OF MUCOSAL HEALING.
50. OC.06.4 RELATIONSHIP BETWEEN MUCOSAL AND INTESTINAL HEALING IN CROHN'S DISEASE MANAGEMENT.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.